Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma
(MedPage Today) -- Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis.
While there was no significant increase in the risk of second... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2022 Category: Hematology Source Type: news
Year in Review: Multiple Myeloma
(MedPage Today) -- Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2022 Category: Hematology Source Type: news
FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma
Teclistamab is now an option after progression on triple-class therapy; however, the FDA also issued a Boxed Warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma
On October 25, 2022, the Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have receiv (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 25, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab
(MedPage Today) -- Treatment options for relapsed/refractory multiple myeloma continue to expand with FDA's accelerated approval of teclistamab (Tecvayli).
The approval stipulates use of the bispecific antibody in adults who have received at least... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 25, 2022 Category: American Health Source Type: news
FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options
HORSHAM, Pa., October 25, 2022– The Janssen Pharmaceutical Companies of Johnson... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 25, 2022 Category: Drugs & Pharmacology Source Type: news
Highlights in Corneal Disorders From AAO 2022 Highlights in Corneal Disorders From AAO 2022
Key data in corneal disorders from AAO include a nontransplant therapy for Fuchs dystrophy, data on corneal adverse events from a myeloma drug, and positive data on lotilaner for Demodex blepharitis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
CAR T Therapy For Drug Resistant Multiple Myeloma
Patients with drug-resistant multiple myeloma find early success with a new CAR T therapy, a recent study finds (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 21, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Kenya: First Ever Bone Marrow Transplant Conducted at Nairobi West Hospital
[Capital FM] Nairobi -- The Nairobi West hospital has successfully conducted the first ever bone marrow transplant in the country, to a female patient ailing from multiple myeloma which is a type of blood cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 19, 2022 Category: African Health Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
AI can improve fracture detection on whole-body trauma CT
An artificial intelligence (AI) algorithm can help to avoid missed fracture...Read more on AuntMinnie.comRelated Reading:
SIIM: AI can detect multiple myeloma lesions on whole-body CT
Whole-body CT cuts ED time for lower extremity fractures
Abbreviated whole-body CT effective for coping with mass-casualty events
What's whole-body CT's place in trauma imaging?
Is whole-body CT necessary after motor vehicle crashes? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2022 Category: Radiology Source Type: news
Risky Breast Cancer Margins; New Myeloma Therapy Shows Promise; Cancer Cell Fungus
(MedPage Today) -- Surgical margins <1 mm in breast-conserving surgery increased the risk of local and distant recurrence. (The BMJ)
CAR T-cell therapy targeting a form of G protein-coupled receptor achieved a high response rate in relapsed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2022 Category: Hematology Source Type: news
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma
(MedPage Today) -- Combination treatment with belantamab mafodotin (belamaf; Blenrep) plus lenalidomide (Revlimid) and dexamethasone appeared effective for relapsed or refractory multiple myeloma, and had a tolerable safety profile, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2022 Category: Hematology Source Type: news
Follow-up Trial of Myeloma Drug'Flopped,' Says FDA Panel Follow-up Trial of Myeloma Drug'Flopped,' Says FDA Panel
Oncopeptides failed to persuade FDA advisers that a post hoc analysis shows a benefit to its myeloma drug, melphalan flufenamide, which received accelerated approval in early 2021.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 23, 2022 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
